Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina
Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

Date: 14-08-2026

To,
The Deputy Manager
(Department of Corporate Services)
BSE Limited
P. J. Towers Dalal Street,
Fort, Mumbai- 400001

Sub: Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Ref.: Scrip Code: 512600
Security Id: ASTALLTD

Respected Sir/ Madam,

Pursuant to the Regulation 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015 (Listing Regulations), the Board of Directors at their meeting held on 14th August, 2026 have considered and approved, the Unaudited Standalone and Consolidated Financial Results of the company for the quarter ended 30th June, 2026 along with the limited review report of the auditors thereon.

The Auditors' Limited Review Report on the said financial results is also attached herewith.

The Board Meeting commenced at 05:00 p.m. (IST) and concluded at 05:38 p.m. (IST)

The aforesaid information is also available on the website of the Company https://astallabs.com.

We request you to take the aforesaid information on record for dissemination through your website.

Thanking you,

Yours Faithfully,

For Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

Mahendra

Mahendra Kumar
(Company Secretary & Compliance Officer)
Membership No.: A71224

SATHULURI & CO.
CHARTERED ACCOUNTANTS

Limited Review Report on Standalone Unaudited Quarterly Financial Results of Astal Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
Board of Directors
Astal Laboratories Limited

We have reviewed the accompanying statement of Standalone unaudited quarterly financial results of **Astal Laboratories Limited** for the quarter ended on 30th June, 2026, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation,2015, (the Regulation) as amended, (the "Listing Regulations').

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

SATHULURI & CO. HYDERABAD CHARTERED ACCOUNTANTS

Off: 11-13-1377/2, Flat No. 401, City Centre Complex, Margadarshi Colony, Kothapet, Hyderabad-500035.
Ph: 9391686797 Email: casathuluri93@gmail.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sathuluri & Co
Chartered Accountants
Firm Reg No.006383S

S.S.Prakash
Partner
M.No.202710

UDIN : 26202710FOVAKA6300

Place: Hyderabad
Date: 14-08-2026

Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605
Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

Statement of Standalone Unaudited Financial Results for the quarter ended 30th June, 2026

(Rs. In Lakhs except Earning per share)

S. No.	Particulars	3 Months Ended	Preceding 3 Months ended	Corsponding 3 Months Ended in Previous Year	Year to Date Figures for Current Period Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	**Revenue**				
	a) From operations	3,951.41	4,091.70	2,532.66	15,599.53
	b) Other Income	3.21	6.63	5.61	19.16
	Total Revenue	**3,954.62**	**4,098.32**	**2,538.27**	**15,618.68**
2	**Expenses**				
	(a) Cost of Material Consumed	4,081.52	3,622.87	2,308.22	15,288.45
	(b) Purchases of stock-in-trade		-		
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	(799.50)	122.72	(161.63)	(1,401.56)
	(d) Employees Benefits expenses	61.82	80.72	44.72	211.26
	(e) Finance Cost	32.79	46.72	30.08	140.91
	(f) Depreciation amortization expenses	17.74	32.10	12.01	68.84
	(g) Other Expenses	64.60	46.02	25.59	224.23
	Total Expenses	**3,458.97**	**3,951.14**	**2,258.98**	**14,532.12**
3	**Profit from ordinary activities before exceptonal Items (1 - 2)**	495.65	147.18	279.29	1,086.56
4	**Exceptional Items - Income/ (Expenses)**				
5	**Profit from ordinary activities before tax (3 - 4)**	495.65	147.18	279.29	1,086.56
6	Tax Expenses				
	(a) Current Tax	103.13	41.73	45.61	258.84
	(b) Deferred Tax	21.83	-3.14	24.71	16.17
7	**Profit/(Loss) for the period (5 -6)**	370.69	108.59	208.96	811.55
8	A (i) Items that will not be reclassified to profit or loss (net of tax)				
	(ii) Income Tax relating to items that will not be reclassified to profit or loss				
	B (i) Items that will not be reclassified to profit or loss (net of tax)				
	(ii) Income Tax relating to items that will not be reclassified to profit or loss				

ASTAL LABORATORIES LIMITED

9	Total Comprehensive Income, net of tax (7 + 8)	370.69	108.59	208.96	811.55
10	Paid up equity share capital (Face Value of Rs.10/- each)	4379.89	4223.12	984.56	4223.12
11	Earning per share (of Rs.10/-each) not annualised				
	(a) Basic	**0.861**	**0.288**	**2.126**	**4.757**
	(b) Diluted	**0.857**	**0.275**	**1.737**	**4.310**

Notes:

1	The above Unaudited Standalone Financial Results of the company for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its meeting held on 14th August, 2026.
2	The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs).
3	Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.
4	These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016
5	The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results.
6	The Company has opted to publish the financial result. The standalone results of the company will be available on the company's website https://astallabs.com/
7	The Company has one Material Wholly Owned Subsidiary Company as on June 30, 2026.

//By the order of the Board//
For Astal Laboratories Limited

Place: Hyderabad
Date: 14/08/2026

ASTAL LABORATORIES LIMITED

SUDHEER KARNA KANKANALA
(Wholetime Director)
DIN: 07591466

Limited Review Report on Consolidated Unaudited Quarterly Financial Results of Astal Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
Board of Directors
Astal Laboratories Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Astal Laboratories Limited** (the "Holding Company") and its subsidiary (the "Holding Company" and its subsidiary together referred to as "the Group"), for the quarter ended 30th June, 2026, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

SATHULURI & CO. HYDERABAD CHARTERED ACCOUNTANTS

Off: 11-13-1377/2, Flat No. 401, City Centre Complex, Margadarshi Colony, Kothapet, Hyderabad-500035.
Ph: 9391686797 Email: casathuluri93@gmail.com

4. The Statement includes the results of the following Subsidiary entities:

   (i) Sriven Pharmachem India Private Limited.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the financial results of 1 Wholly Owned Subsidiary included in the consolidated unaudited financial results, whose interim financial results reflect total revenue of Rs. 6152.77 Lakhs and Rs. 9366.87 Lakhs total net profit after tax of Rs. 571.48 Lakhs and Rs. 658.66 Lakhs and total comprehensive income of Rs. 571.48 Lakhs and Rs. 658.66 Lakhs, for the quarter ended June 30, 2026 and for the period from 14th January to March 31, 2026 respectively as considering the consolidated unaudited financial results. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

For Sathuluri & Co
Chartered Accountants
Firm Reg No.006383S

SATHULURI & CO. HYDERABAD CHARTERED ACCOUNTANTS

S.S.Prakash
Partner
M.No.202710

UDIN : 26202710ZPNDNH8953

Place: Hyderabad
Date: 14-08-2026

Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

Statement of Consolidated Unaudited Financial Results for the quarter ended 30th June, 2026

(Rs. In Lakhs except Earning per share)

S. No.	Particulars	3 Months Ended	Preceding 3 Months ended	Corsponding 3 Months Ended in Previous Year	Year to Date Figures for Current Period Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	**Revenue**				
	a) From operations	10,093.58	13,404.90	-	24,912.73
	b) Other Income	13.81	9.62	-	22.15
	Total Revenue	**10,107.39**	**13,414.52**	**-**	**24,934.88**
2	**Expenses**				
	(a) Cost of Material Consumed	10,011.74	10,824.99	-	22,490.57
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	(1,739.97)	935.71	-	(588.57)
	(d) Employees Benefits expenses	314.82	371.61	-	502.15
	(e) Finance Cost	117.60	109.05	-	203.25
	(f) Depreciation amortization expenses	86.01	86.08	-	122.82
	(g) Other Expenses	282.18	253.42	-	431.62
	Total Expenses	**9,072.38**	**12,580.87**	**-**	**23,161.85**
3	**Profit from ordinary activities before exceptonal Items (1 - 2)**	1,035.01	833.65	-	1,773.03
4	**Exceptional Items - Income/ (Expenses)**				
5	**Profit from ordinary activities before tax (3 - 4)**	1,035.01	833.65	-	1,773.03
6	Tax Expenses				
	(a) Current Tax	119.70	50.93	-	268.04
	(b) Deferred Tax	(26.86)	14.73	-	34.05
7	**Profit/(Loss) for the period (5 -6)**	**942.17**	**767.99**	**-**	**1,470.94**
8	A (i) Items that will not be reclassified to profit or loss (net of tax)				
	(ii) Income Tax relating to items that will not be reclassified to profit or loss				
	B (i) Items that will not be reclassified to profit or loss (net of tax)				

ASTAL LABORATORIES LIMITED

	(ii) Income Tax relating to items that will not be reclassified to profit or loss				
9	Total Comprehensive Income, net of tax (7 + 8)	942.17	767.99	-	1,470.94
10	Paid up equity share capital (Face Value of Rs.10/- each)	4379.89	4223.12	-	4223.12
11	Earning per share (of Rs.10/-each) *not annualised*				
	(a) Basic	**2.188**	**2.039**	-	**4.757**
	(b) Diluted	**2.178**	**1.947**	-	**4.310**

Notes:

1	The above Unaudited Consolidated Financial Results of the company for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its meeting held on 14th August, 2026.
2	The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs).
3	Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.
4	These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016
5	The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results.
6	The Company has opted to publish the financial result. The standalone results of the company will be available on the company's website https://astallabs.com/
7	The Company has one Material Wholly Owned Subsidiary Company as on June 30, 2026. The requirement of Consolidation for the Corsponding 3 Months Ended in Previous Year as on 30.06.2025 was not applicable.

//By the order of the Board//
For Astal Laboratories Limited

Place: Hyderabad
Date: 14/08/2026

ASTAL LABORATORIES LIMITED

SUDHEER KARNA KANKANALA
(Wholetime Director)
DIN: 07591466